• ReutersNovartis throws down gauntlet to Roche with Rituxan copy

    ZURICH Switzerland’s Novartis increased pressure on Roche’s ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.Rixathon, from Novartis’s Sandoz generics unit, follows Celltrion’s Truxima that secured the European Commission’s blessing in February to be used against diseases including non-Hodgkin’s lymphoma and Read more...

  • ReutersClovis's ovarian cancer drug set for label expansion, shares soar

    n”Positive late-stage data on Clovis Oncology Inc’s ovarian cancer drug, Rubraca, could help widen the use of the therapy and differentiate it from rivals, the U.S. biotech said on Monday, sending its shares soaring 48 percent.The drug, like Tesaro Inc’s Zejula and AstraZeneca Plc’s Lynparza, belongs to a closely watched class of new medicines called PARP inhibitors, which blocks enzymes Read more...

  • The San Diego Union-TribuneBiotechs find stability despite turbulence, new study finds

    In its relatively brief lifetime, the biotechnology industry has swung between exuberance and despondency. In an uncertain environment, the best path is to stay the course, according to a new report from the professional services firm EY.To stay the course means continuing to invest in new technologies, trusting in “the long development cycles of biotech” to provide return on investment Read more...

  • The San Diego Union-TribuneBackstory to the 2017 biotech convention in San Diego

    Today’s Backstory features Bradley J. Fikes, who writes about biotechnology and life science for The San Diego Union-Tribune.His article about some of the hottest fields in the life sciences appears on the front page of Sunday’s print edition. It’s timed to the start of the BIO convention, the world’s largest biotech gathering, which will take place this week at the Read more...

  • The San Diego Union-TribuneBiotechs find stability despite turbulence, new study finds

    In its relatively brief lifetime, the biotechnology industry has swung between exuberance and despondency. In an uncertain environment, the best path is to stay the course, according to a new report from the professional services firm EY.To stay the course means continuing to invest in new technologies, trusting in “the long development cycles of biotech” to provide return on investment Read more...

  • NJRutgers appoints new leader for Board of Governors

    NEW BRUNSWICK — A retired biotech industry entrepreneur will be the new leader of Rutgers University’s governing board.  Sandy Stewart, the current vice chairman of the university’s Board of Governors, will become board chairman for at least one year beginning July 1.  Stewart, a 1981 Rutgers-Camden alumnus, replaces Greg Brown, the Motorola executive who is stepping down from the board’s Read more...

  • ArsTechnicaIn Borne, there’s a biotech apocalypse so weird it’s almost plausible

    Wick and Rachel are barely surviving at the fringes of a city destroyed by an apocalypse so bizarre that it almost defies description. All we know is that a skyscraper-sized floating bear named Mord frequently zooms across the sky, terrorizing the area’s remaining inhabitants. In bestselling author Jeff VanderMeer’s new novel, Borne, we’re plunged into a future environmental hellscape. The best Read more...

  • ReutersGoogle bets on European biotech drugs, backs new fund

    LONDON Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis (NOVN.S) in a new $300 million fund run by leading life sciences investment firm Medicxi.The move shows Google casting an increasingly wide net as it pumps cash into global medical research, seeding what it believes will become a core Read more...

  • ReutersGoogle bets on European biotech drugs, backs new fund

    LONDON Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.The move shows Google casting an increasingly wide net as it pumps cash into global medical research, seeding what it believes will become a core long-term Read more...

  • ReutersSanofi to invest further in biologics

    PARIS Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.In contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in cardiovascular, neurology and cancer diseases.Experts say Read more...